SPECIALISATION:
Exclusively working in lentivirus
CDMO BUSINESS MODEL:
Covering the different phases
CUTTING-EDGE TECHNOLOGIES:
Seal of Excellence from European Commission
SCIENTIFIC EXPERTISE:
Own lentivirus-based technology (Lentisoma)
CUSTOMISED APPROACH TO PROJECTS:
Slots availability in a timely manner
BROAD EXPERTISE AND EXPERIENCE OF OUR TEAM:
Manufacture of lentiviral vectors for CAR-T/TCR and gene therapy clinical trials
THE MOST INNOVATIVE EQUIPMENT AVAILABLE:
- iCELLis® bioreactor technology
- Compatible equipment at R&D and GMP suites
- More than 1600 m2 (17000 ft2) labs
MANUFACTURING PLATFORM DEVELOPMENT:
Increased final yield compared with regular protocols
POTENTIALITY:
Facilities, capability and infrastructure to increase current capacity
INTERNATIONAL COMPANY:
US and European customers
